Visirna Therapeutics Hk Limited
Clinical trials sponsored by Visirna Therapeutics Hk Limited, explained in plain language.
-
New shot could slash Sky-High cholesterol in rare genetic disease
Disease control OngoingThis study tests a new medicine called VSA003 in 46 Chinese teenagers and adults with homozygous familial hypercholesterolemia (HoFH), a genetic condition causing extremely high cholesterol and early heart disease. VSA003 uses RNAi technology to lower a protein (ANGPTL3) that con…
Phase: PHASE3 • Sponsor: Visirna Therapeutics HK Limited • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New siRNA drug aims to reverse liver damage in NASH patients
Disease control OngoingThis study tests an experimental drug called VSA006 in 48 Chinese adults with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease. The drug uses siRNA technology to lower a protein linked to liver damage. The goal is to see if VSA006 can improve liver scarring and …
Phase: PHASE2 • Sponsor: Visirna Therapeutics HK Limited • Aim: Disease control
Last updated May 14, 2026 12:03 UTC